|
TPM1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.577620E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.863900E-02 |
| Normal-vs-Stage2 |
8.032200E-02 |
| Normal-vs-Stage3 |
4.987800E-01 |
| Normal-vs-Stage4 |
3.207600E-01 |
| Stage1-vs-Stage2 |
4.941400E-01 |
| Stage1-vs-Stage3 |
5.016400E-01 |
| Stage1-vs-Stage4 |
7.761200E-01 |
| Stage2-vs-Stage3 |
2.929200E-01 |
| Stage2-vs-Stage4 |
4.604200E-01 |
| Stage3-vs-Stage4 |
7.570400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.382770E-01 |
| Normal-vs-AfricanAmerican |
6.758200E-01 |
| Normal-vs-Asian |
5.787600E-01 |
| Caucasian-vs-AfricanAmerican |
2.217800E-01 |
| Caucasian-vs-Asian |
4.543400E-01 |
| AfricanAmerican-vs-Asian |
4.524200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.947400E-01 |
| Normal-vs-Female |
1.417950E-01 |
| Male-vs-Female |
6.147000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.530000E-02 |
| Normal-vs-Age(41-60Yrs) |
1.152180E-01 |
| Normal-vs-Age(61-80Yrs) |
5.544200E-01 |
| Normal-vs-Age(81-100Yrs) |
7.620800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.168200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.929800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.289000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.361000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.974600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.367200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.708600E-01 |
| Classical-VS-Follicular |
2.067200E-01 |
| Classical-VS-Other |
5.738600E-01 |
| Classical-VS-Normal |
2.548600E-01 |
| Tall-VS-Follicular |
4.703600E-01 |
| Tall-VS-Other |
8.759800E-01 |
| Tall-VS-Normal |
8.310800E-01 |
| Follicular-VS-Other |
3.415800E-01 |
| Follicular-VS-Normal |
6.356000E-02 |
| Other-VS-Normal |
9.360000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.669700E-02 |
| Normal-vs-N1 |
1.636420E-01 |
| N0-vs-N1 |
8.454000E-01 |
|
|
